Sagimet Biosciences Inc. (SGMT) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 53 transactions totaling $2.6M, demonstrating a bullish sentiment with $51.3K in net insider flow. The most recent transaction on Feb 19, 2026 involved a transaction of 88,000 shares valued at $0.
No significant insider buying has been recorded for SGMT in the recent period.
No significant insider selling has been recorded for SGMT in the recent period.
Based on recent SEC filings, insider sentiment for SGMT is bullish with an Insider Alignment Score of 51/100 and a net flow of $51.3K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Sagimet Biosciences Inc. (SGMT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading SGMT stock, having executed 53 transactions in the past 90 days. The most active insider is Beth C. Seidenberg (Executive), who has made 5 transactions totaling $750.0K.
Get notified when executives and directors at SGMT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Chauche Thierry | Chief Financial Officer | Award | 88,000 | $N/A | $0 | C-Suite |
| Feb 19, 2026 | Chauche Thierry | Chief Financial Officer | Award | 44,000 | $N/A | $0 | C-Suite |
| Nov 20, 2025 | Kemble George | Executive | Sale | 37,688 | $7.69 | $289.8K | |
| Nov 4, 2025 | Rozek Elizabeth | Executive | Award | 9,855 | $N/A | $0 | |
| Jul 21, 2025 | Rozek Elizabeth | Executive | Sale | 10,780 | $9.13 | $98.4K | |
| Jul 21, 2025 | Bruno Martins Eduardo | Executive | Sale | 8,277 | $9.13 | $75.6K | |
| Jul 21, 2025 | Happel David | Executive | Sale | 65,478 | $9.13 | $597.8K | Large |
| Jul 23, 2024 | Kemble George | Executive | Sale | 23,625 | $3.17 | $74.9K | 10b5-1 |
| Jul 19, 2024 | Kemble George | Executive | Sale | 14,062 | $3.10 | $43.6K | |
| Jul 19, 2024 | Rozek Elizabeth | Executive | Sale | 10,914 | $3.10 | $33.8K | |
| Jul 19, 2024 | Bruno Martins Eduardo | Executive | Sale | 8,357 | $3.10 | $25.9K | |
| Mar 26, 2024 | Happel David | Executive | Purchase | 12,100 | $5.27 | $63.8K | |
| Jan 29, 2024 | Associates 13 Lp New Enterprise | Executive | Other | 850,000 | $N/A | $0 | |
| Jan 29, 2024 | Gp, Ltd Nea 13 | Executive | Other | 260,950 | $N/A | $0 | |
| Jan 29, 2024 | Gp, Ltd Nea 13 | Executive | Other | 260,950 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 5 | $1.3M | 50.7% |
Sale(S) | 9 | $1.3M | 48.7% |
Exercise (Options)(X) | 1 | $10.6K | 0.4% |
Exercise(M) | 1 | $4.4K | 0.2% |
Award(A) | 9 | $0 | 0.0% |
Other(J) | 20 | $0 | 0.0% |
Disposition(D) | 2 | $0 | 0.0% |
Conversion(C) | 6 | $0 | 0.0% |
Insider activity at Sagimet Biosciences Inc. shows mixed signals across all time. While $1.3M in purchases indicates some executive confidence,$1.3M in sales balances the picture, resulting in a modest net flow of $51.3K.14 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Beth C. Seidenberg, has transacted $750.0K during this period.